{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:01:40Z","timestamp":1792033300332,"version":"4.4.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.vaccine.2025.126878","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T14:08:41Z","timestamp":1741788521000},"page":"126878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Immunogenicity of pre-exposure rabies vaccination comparing number of doses and routes of administration: A systematic review and meta-analyses"],"prefix":"10.1016","volume":"53","author":[{"given":"Phaedra","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Montroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryna","family":"Warshawsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elissa M.","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"Coward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Killikelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vaccine.2025.126878_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003709","article-title":"Estimating the global burden of endemic canine rabies","volume":"9","author":"Hampson","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2025.126878_bb0015","series-title":"Rabies Geneva","author":"World Health Organization (WHO)","year":"2024"},{"issue":"16","key":"10.1016\/j.vaccine.2025.126878_bb0025","first-page":"201","article-title":"Rabies vaccines: WHO position paper \u2013 April 2018","volume":"93","author":"World Health Organization (WHO)","year":"2018","journal-title":"Wkly Epidemiol Rec"},{"issue":"37","key":"10.1016\/j.vaccine.2025.126878_bb0030","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1016\/j.vaccine.2018.06.061","article-title":"Rabies vaccines: WHO position paper, April 2018 - Recommendations","volume":"36","author":"World Health Organization (WHO)","year":"2018","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2025.126878_bb0035","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3390\/v8080231","article-title":"Subversion of the immune response by rabies virus","volume":"8","author":"Scott","year":"2016","journal-title":"Viruses"},{"issue":"5","key":"10.1016\/j.vaccine.2025.126878_bb0040","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ame2.12273","article-title":"Regulation of innate immune responses by rabies virus","volume":"5","author":"Zhang","year":"2022","journal-title":"Animal Model Exp Med"},{"issue":"18","key":"10.1016\/j.vaccine.2025.126878_bb0045","doi-asserted-by":"crossref","first-page":"619","DOI":"10.15585\/mmwr.mm7118a2","article-title":"Use of a modified Preexposure prophylaxis vaccination schedule to prevent human rabies: recommendations of the advisory committee on immunization practices - United States, 2022","volume":"71","author":"Rao","year":"2022","journal-title":"Morb Mortal Wkly Rep"},{"issue":"7","key":"10.1016\/j.vaccine.2025.126878_bb0050","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.vaccine.2021.01.023","article-title":"Immunogenicity after pre- and post-exposure rabies vaccination: a systematic review and dose-response meta-analysis","volume":"39","author":"Xu","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126878_bb0055","doi-asserted-by":"crossref","first-page":"A99","DOI":"10.1016\/j.vaccine.2018.11.072","article-title":"An overview of the immunogenicity and effectiveness of current human rabies vaccines administered by intradermal route","volume":"37","author":"Denis","year":"2019","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126878_bb0060","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2471\/BLT.16.173039","article-title":"Pre-exposure rabies prophylaxis: a systematic review","volume":"95","author":"Kessels","year":"2017","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2025.126878_bb0065","first-page":"372","article-title":"Statement: an updated guideline for reporting systematic reviews","volume":"2021","author":"Page","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2025.126878_bb0070","series-title":"World Health Organization (WHO) Secretariat, editors. Background paper: Proposed revision of the policy on rabies vaccines and rabies immunoglobulins. Meeting of the Strategic Advisory Group of Experts on Immunization","author":"Strategic Advisory Group of Experts (SAGE) on Immunization Working Group on Rabies vaccines and immunoglobulins","year":"2017"},{"key":"10.1016\/j.vaccine.2025.126878_bb0075","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS peer review of electronic search strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.vaccine.2025.126878_bb0080","first-page":"1","article-title":"Evidence summaries: the evolution of a rapid review approach","author":"Khangura","year":"2012","journal-title":"Syst Rev"},{"key":"10.1016\/j.vaccine.2025.126878_bb0090","series-title":"Cochrane handbook for systematic reviews of interventions. Version 6.4 ed: Cochrane","article-title":"Chapter 10: Analysing data and undertaking meta-analyses","author":"Higgins","year":"2023"},{"key":"10.1016\/j.vaccine.2025.126878_bb0095","first-page":"353","article-title":"GRADE evidence to decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: introduction","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126878_bb0105","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0264-410X(89)90050-9","article-title":"Comparative study of the safety and protective value, in pre-exposure use, of rabies vaccine cultivated on human diploid cells (HDCV) and of the new vaccine grown on Vero cells","volume":"7","author":"Ajjan","year":"1989","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126878_bb0110","first-page":"185","article-title":"Immunogenicity and safety of WHO-approved TRC-ID regimen with a chromatographically purified Vero cell rabies vaccine with or without rabies immunoglobulin in children","volume":"17","author":"Angsuwatcharakon","year":"2018","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126878_bb0115","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2310\/7060.2004.19001","article-title":"Safety and immunogenicity of a new chromatographically purified rabies vaccine in comparison to the human diploid cell vaccine","volume":"11","author":"Arora","year":"2004","journal-title":"J Travel Med"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126878_bb0120","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4161\/hv.26456","article-title":"Safety and immunogenicity study of a new purified chick embryo cell rabies vaccine Vaxirab-N (pitman\u2013Moore strain) manufactured in India","volume":"10","author":"Ashwath Narayana","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"10.1016\/j.vaccine.2025.126878_bb0125","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.1987.03390080049028","article-title":"Preexposure immunization with intradermal human diploid cell rabies vaccine: risks and benefits of primary and booster vaccination","volume":"257","author":"Bernard","year":"1987","journal-title":"JAMA"},{"issue":"40","key":"10.1016\/j.vaccine.2025.126878_bb0130","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1016\/j.vaccine.2016.08.005","article-title":"A randomized non-inferiority clinical study to assess post-exposure prophylaxis by a new purified vero cell rabies vaccine (Rabivax-S) administered by intramuscular and intradermal routes","volume":"34","author":"Bose","year":"2016","journal-title":"Vaccine"},{"issue":"9\u201310","key":"10.1016\/j.vaccine.2025.126878_bb0135","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0264-410X(00)00342-X","article-title":"Purified Chick embryo cell culture rabies vaccine: interchangeability with human diploid cell culture rabies vaccine and comparison of one versus two-dose post-exposure booster regimen for previously immunized persons","volume":"19","author":"Briggs","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126878_bb0140","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijid.2021.09.025","article-title":"Immunogenicity of 2-dose pre-exposure rabies vaccine co-administered with quadrivalent influenza vaccine in children","volume":"112","author":"Chantasrisawad","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126878_bb0145","first-page":"105","article-title":"Human rabies immunoprophylaxis using HDC (MRC-5) vaccine","volume":"40","author":"Cox","year":"1978","journal-title":"Dev Biol Stand"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126878_bb0150","article-title":"One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series","volume":"23","author":"Cramer","year":"2016","journal-title":"J Travel Med"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126878_bb0155","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1590\/S0034-89102010005000005","article-title":"Equivalence between pre-exposure schemes for human rabies and evaluation of the need for serological monitoring","volume":"44","author":"Cunha","year":"2010","journal-title":"Rev Saude Publica"},{"issue":"5","key":"10.1016\/j.vaccine.2025.126878_bb0160","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0264-410X(89)90152-7","article-title":"Two-year comparative trial on the immunogenicity and adverse effects of purified chick embryo cell rabies vaccine for pre-exposure immunization","volume":"7","author":"Dreesen","year":"1989","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2025.126878_bb0165","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1093\/infdis\/jiz645","article-title":"Serologic response of 2 versus 3 doses and intradermal versus intramuscular Administration of a Licensed Rabies Vaccine for Preexposure prophylaxis","volume":"221","author":"Endy","year":"2020","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126878_bb0170","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/infdis\/156.1.50","article-title":"Rabies Preexposure prophylaxis with human diploid cell rabies vaccine: a dose-response study","volume":"156","author":"Fishbein","year":"1987","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126878_bb0175","article-title":"Immunogenicity and 1-year boostability of a three-dose intramuscular rabies pre-exposure prophylaxis schedule in adults receiving immunosuppressive monotherapy: a prospective single-Centre clinical trial","volume":"30","author":"Garrido","year":"2023","journal-title":"J Travel Med"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126878_bb0180","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1708-8305.1999.tb00524.x","article-title":"Immunogenicity of rabies Postexposure booster injections in subjects who had previously received intradermal Preexposure vaccination","volume":"6","author":"Jaijaroensup","year":"1999","journal-title":"J Travel Med"},{"issue":"36","key":"10.1016\/j.vaccine.2025.126878_bb0185","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1016\/j.vaccine.2019.07.055","article-title":"A randomized open-label trial of 2-dose or 3-dose pre-exposure rabies prophylaxis among Thai children","volume":"37","author":"Janewongwirot","year":"2019","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126878_bb0190","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.tmaid.2015.05.008","article-title":"Evaluation of rabies immunogenicity and tolerability following a purified chick embryo cell rabies vaccine administered concomitantly with a Japanese encephalitis vaccine","volume":"13","author":"Jelinek","year":"2015","journal-title":"Travel Med Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2025.126878_bb0195","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/tax033","article-title":"Single visit rabies pre-exposure priming induces a robust anamnestic antibody response after simulated post-exposure vaccination: results of a dose-finding study","volume":"24","author":"Jonker","year":"2017","journal-title":"J Travel Med"},{"issue":"19","key":"10.1016\/j.vaccine.2025.126878_bb0200","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1016\/j.vaccine.2011.12.028","article-title":"One clinic visit for pre-exposure rabies vaccination (a preliminary one year study)","volume":"30","author":"Khawplod","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126878_bb0205","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1708-8305.2007.00120.x","article-title":"Immunogenicity study of abbreviated rabies Preexposure vaccination schedules","volume":"14","author":"Khawplod","year":"2007","journal-title":"J Travel Med"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126878_bb0210","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1086\/344954","article-title":"Prospective immunogenicity study of multiple intradermal injections of rabies vaccine in an effort to obtain an early immune response without the use of immunoglobulin","volume":"35","author":"Khawplod","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2025.126878_bb0215","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/jcm.28.8.1847-1850.1990","article-title":"Comparison of human immune responses to purified Vero cell and human diploid cell rabies vaccines by using two different antibody titration methods","volume":"28","author":"Kitala","year":"1990","journal-title":"J Clin Microbiol"},{"issue":"24","key":"10.1016\/j.vaccine.2025.126878_bb0220","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.vaccine.2013.03.050","article-title":"Safety and immunogenicity of a new purified vero cell rabies vaccine (PVRV) administered by intramuscular and intradermal routes in healthy volunteers","volume":"31","author":"Kulkarni","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126878_bb0225","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0011-393X(04)90004-5","article-title":"A comparison of the tolerability of two dilution volumes (0.5 mL and 1.0 mL) of a purified chick embryo cell rabies vaccine administered intramuscularly to healthy adult volunteers: a randomized, intraindividual, assessor-blind study","volume":"65","author":"Kulkarni","year":"2004","journal-title":"Curr Ther Res Clin Exp"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126878_bb0230","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1006\/biol.1998.0156","article-title":"Immunogenicity and safety in adults of a new chromatographically purified Vero-cell rabies vaccine (CPRV): a randomized, double-blind trial with purified Vero-cell rabies vaccine (PVRV)","volume":"26","author":"Lang","year":"1998","journal-title":"Biologicals"},{"issue":"36","key":"10.1016\/j.vaccine.2025.126878_bb0235","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.1016\/j.vaccine.2010.06.062","article-title":"Safety and efficacy of novel dermal and epidermal microneedle delivery systems for rabies vaccination in healthy adults","volume":"28","author":"Laurent","year":"2010","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2025.126878_bb0240","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/infdis\/145.2.720","article-title":"Antibody responses to human diploid cell vaccine for rabies with and without human rabies immune globulin","volume":"145","author":"Mertz","year":"1982","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126878_bb0245","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S1473-3099(23)00452-8","article-title":"Boostability after single-visit pre-exposure prophylaxis with rabies vaccine: a randomised controlled non-inferiority trial","volume":"24","author":"Overduin","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126878_bb0250","first-page":"83","article-title":"What happens if intradermal injections of rabies vaccine are partially or entirely injected subcutaneously?","volume":"68","author":"Phanuphak","year":"1990","journal-title":"Bull World Health Organ"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126878_bb0255","first-page":"33","article-title":"Humoral and cell-mediated immune responses to various economical regimens of purified Vero cell rabies vaccine","volume":"5","author":"Phanuphak","year":"1987","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"18","key":"10.1016\/j.vaccine.2025.126878_bb0260","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/j.vaccine.2013.02.058","article-title":"A serum-free, purified vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab for pre-exposure use in healthy adults: results from a randomized controlled phase-II trial","volume":"31","author":"Pichon","year":"2013","journal-title":"Vaccine"},{"issue":"33","key":"10.1016\/j.vaccine.2025.126878_bb0265","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1016\/j.vaccine.2022.06.040","article-title":"Safety and immunogenicity of a serum-free purified Vero rabies vaccine in healthy adults: a randomised phase II pre-exposure prophylaxis study","volume":"40","author":"Pichon","year":"2022","journal-title":"Vaccine"},{"issue":"35","key":"10.1016\/j.vaccine.2025.126878_bb0270","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1016\/j.vaccine.2022.06.061","article-title":"Serum-free purified Vero rabies vaccine is safe and immunogenic in children: results of a randomized phaseII pre-exposure prophylaxis regimen study","volume":"40","author":"Quiambao","year":"2022","journal-title":"Vaccine"},{"issue":"36","key":"10.1016\/j.vaccine.2025.126878_bb0275","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1016\/j.vaccine.2022.07.037","volume":"40","author":"Quiambao","year":"2022","journal-title":"Vaccine"},{"issue":"34","key":"10.1016\/j.vaccine.2025.126878_bb0280","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1016\/j.vaccine.2017.06.083","article-title":"A single center, open label study of intradermal administration of an inactivated purified chick embryo cell culture rabies virus vaccine in adults","volume":"35","author":"Recuenco","year":"2017","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126878_bb0285","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1017\/S0950268800066899","article-title":"Persistence of rabies antibody 5 years after pre-exposure prophylaxis with human diploid cell antirabies vaccine and antibody response to a single booster dose","volume":"99","author":"Rodrigues","year":"1987","journal-title":"Epidemiol Infect"},{"issue":"11","key":"10.1016\/j.vaccine.2025.126878_bb0290","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/00006454-199811000-00007","article-title":"Persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunizations with purified Vero cell rabies vaccine","volume":"17","author":"Sabchareon","year":"1998","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126878_bb0295","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1086\/520143","article-title":"A new Vero cell rabies vaccine: results of a comparative trial with human diploid cell rabies vaccine in children","volume":"29","author":"Sabchareon","year":"1999","journal-title":"Clin Infect Dis"},{"issue":"24","key":"10.1016\/j.vaccine.2025.126878_bb0300","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1016\/j.vaccine.2010.03.064","article-title":"Immunogenicity and safety study of Indirab: a Vero cell based chromatographically purified human rabies vaccine","volume":"28","author":"Sampath","year":"2010","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2025.126878_bb0305","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.vaccine.2004.08.001","article-title":"An immunogenicity study of a newly introduced purified vero cell rabies vaccine (Abhayrab) manufactured in India","volume":"23","author":"Sampath","year":"2005","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2025.126878_bb0310","doi-asserted-by":"crossref","first-page":"365","DOI":"10.4161\/hv.4.5.5987","article-title":"Protecting Indian schoolchildren against rabies: pre-exposure vaccination with purified chick embryo cell vaccine (PCECV) or purified verocell rabies vaccine (PVRV)","volume":"4","author":"Shanbag","year":"2008","journal-title":"Hum Vaccin"},{"issue":"50","key":"10.1016\/j.vaccine.2025.126878_bb0315","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1016\/j.vaccine.2008.08.068","article-title":"A pilot study on intradermal vaccination of Japanese rabies vaccine for pre-exposure immunization","volume":"26","author":"Shiota","year":"2008","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126878_bb0320","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/cid\/ciy513","article-title":"Preexposure intradermal rabies vaccination: a noninferiority trial in healthy adults on shortening the vaccination schedule from 28 to 7 days","volume":"68","author":"Soentjens","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2025.126878_bb0325","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1086\/515267","article-title":"Antibody persistence following Preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy","volume":"177","author":"Strady","year":"1998","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126878_bb0330","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4269\/ajtmh.1987.36.160","article-title":"Early antibody responses to rabies post-exposure vaccine regimens","volume":"36","author":"Suntharasamai","year":"1987","journal-title":"Am J Trop Med Hyg"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126878_bb0335","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1586\/14760584.2014.971764","article-title":"Safety and immunogenicity of chromatographically purified Vero cell rabies vaccine for intradermal pre- and post-exposure rabies prophylaxis","volume":"13","author":"Tantawichien","year":"2014","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126878_bb0340","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1086\/313610","article-title":"Safety and immunogenicity of Preexposure rabies vaccination in children infected with human immunodeficiency virus type 1","volume":"30","author":"Thisyakorn","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"14","key":"10.1016\/j.vaccine.2025.126878_bb0345","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/j.vaccine.2016.09.069","article-title":"Safety, tolerability and efficacy of intradermal rabies immunization with DebioJect\u2122","volume":"35","author":"Vescovo","year":"2017","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126878_bb0350","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0264-410X(86)90138-6","article-title":"An evaluation of second generation tissue culture rabies vaccines for use in man: a four-vaccine comparative immunogenicity study using a pre-exposure vaccination schedule and an abbreviated 2-1-1 postexposure schedule","volume":"4","author":"Vodopija","year":"1986","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126878_bb0355","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000224","article-title":"A simplified 4-site economical intradermal post-exposure rabies vaccine regimen: a randomised controlled comparison with standard methods","volume":"2","author":"Warrell","year":"2008","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126878_bb0360","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taac029","article-title":"Two-year immunogenicity of a pre-exposure rabies vaccination administered as a two-dose schedule","volume":"29","author":"Windels","year":"2022","journal-title":"J Travel Med"},{"issue":"13","key":"10.1016\/j.vaccine.2025.126878_bb0365","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.vaccine.2013.01.035","article-title":"Rabies neutralizing antibody after 2 intradermal doses on days 0 and 21 for pre-exposure prophylaxis","volume":"31","author":"Wongsaroj","year":"2013","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2025.126878_bb0370","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/cid\/ciy983","article-title":"Comparative immunogenicity and safety trial of 2 different schedules of single-visit intradermal rabies Postexposure vaccination","volume":"69","author":"Soentjens","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"48","key":"10.1016\/j.vaccine.2025.126878_bb0375","doi-asserted-by":"crossref","first-page":"5959","DOI":"10.1016\/j.vaccine.2016.09.058","article-title":"Rabies pre-exposure prophylaxis elicits long-lasting immunity in humans","volume":"34","author":"Mansfield","year":"2016","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.vaccine.2025.126878_bb0380","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1016\/S0264-410X(00)00054-2","article-title":"Predictive factors for the neutralizing antibody response following pre-exposure rabies immunization: validation of a new booster dose strategy","volume":"18","author":"Strady","year":"2000","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126878_bb0385","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/cid\/ciy420","article-title":"Rabies antibody response after booster immunization: a systematic review and Meta-analysis","volume":"67","author":"Langedijk","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"51","key":"10.1016\/j.vaccine.2025.126878_bb0390","doi-asserted-by":"crossref","first-page":"7149","DOI":"10.1016\/j.vaccine.2009.09.034","article-title":"Rabies virus pathogenesis in relationship to intervention with inactivated and attenuated rabies vaccines","volume":"27","author":"Franka","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126878_bb0395","series-title":"Plotkin\u2019s vaccines","first-page":"17","article-title":"Chapter 2 - vaccine immunology","author":"Siegrist","year":"2023"},{"issue":"6","key":"10.1016\/j.vaccine.2025.126878_bb0400","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1093\/infdis\/jiab034","article-title":"Long-term memory response after a single intramuscular rabies booster vaccination 10-24 years after primary immunization","volume":"226","author":"De Pijper","year":"2022","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2025.126878_bb0405","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1086\/598998","article-title":"Bats in the bedroom, bats in the belfry: reanalysis of the rationale for rabies Postexposure prophylaxis","volume":"48","author":"De Serres","year":"2009","journal-title":"Clin Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25001756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25001756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T06:24:48Z","timestamp":1745130288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25001756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":77,"alternative-id":["S0264410X25001756"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126878","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of pre-exposure rabies vaccination comparing number of doses and routes of administration: A systematic review and meta-analyses","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126878","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126878"}}